VM4 Stock Overview
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vanda Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.72 |
| 52 Week High | US$6.25 |
| 52 Week Low | US$3.08 |
| Beta | 0.78 |
| 1 Month Change | 32.58% |
| 3 Month Change | 39.65% |
| 1 Year Change | -15.71% |
| 3 Year Change | -66.29% |
| 5 Year Change | -68.89% |
| Change since IPO | -38.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| VM4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 25.5% | -5.1% | -2.0% |
| 1Y | -15.7% | -21.1% | -0.3% |
Return vs Industry: VM4 exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: VM4 underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| VM4 volatility | |
|---|---|
| VM4 Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VM4's share price has been volatile over the past 3 months.
Volatility Over Time: VM4's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 203 | Mihael Polymeropoulos | www.vandapharma.com |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia.
Vanda Pharmaceuticals Inc. Fundamentals Summary
| VM4 fundamental statistics | |
|---|---|
| Market cap | €259.17m |
| Earnings (TTM) | €2.35m |
| Revenue (TTM) | €180.77m |
110.1x
P/E Ratio1.4x
P/S RatioIs VM4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VM4 income statement (TTM) | |
|---|---|
| Revenue | US$192.64m |
| Cost of Revenue | US$14.80m |
| Gross Profit | US$177.84m |
| Other Expenses | US$175.34m |
| Earnings | US$2.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.044 |
| Gross Margin | 92.32% |
| Net Profit Margin | 1.30% |
| Debt/Equity Ratio | 0% |
How did VM4 perform over the long term?
See historical performance and comparison